GT Medical Technologies Welcomes New Gammatile® Center Of Excellence Program Designation

(MENAFN- PR Newswire) The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements.

The following physicians are now recognized with achievement:

• Charles G. Kulwin, MD, Neurosurgeon
• Troy D. Payner, MD, Neurosurgeon
• Kushal J. Shah, MD, Neurosurgeon

"With GammaTile, we can deliver radiation directly to the tumor site at the time of surgery without any delay," said Dr. Charles G. Kulwin, a neurosurgeon at Goodman Campbell Brain and Spine. "We are proud to provide such an innovative treatment option at Goodman Campbell Brain and Spine and be recognized as a GammaTile Center of Excellence. We are always looking for opportunities to give patients hope where options have been historically limited."

GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are at their lowest levels. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.¹

About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.

About GammaTile
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within-placed into the surgical cavity at the time of tumor removal-GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.

Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile and follow @GammaTile on Facebook , Instagram , LinkedIn and X .

Media Contact
Dawn Fallon
New Dawn Communications LLC
[email protected]
732-771-7808

References

1. Garcia MA et al. J Neurooncol. 166:203-212 (2024).

SOURCE GT Medical Technologies

MENAFN30062025003732001241ID1109741353